Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FRK | P42685 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28763820 | 1.00 | CSF1R (0.46) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL15864698 | 0.84 | CCNC (0.49) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL12056811 | 0.83 | CCNT1 (0.41) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL12056806 | 0.82 | CSF1R (0.42) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL5206065 | 0.82 | CSF1R (0.49) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL906189 | 0.82 | CSF1R (0.43) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL12056807 | 0.81 | CDK2 (0.44) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL12056805 | 0.81 | CSF1R (0.43) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL906147 | 0.81 | CSF1R (0.41) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL12056808 | 0.81 | HDAC6 (0.45) | CSF1RCDK2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2277865-B1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2014-11-12 | — | — | EP | disclosed |
| US-20140221396-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221396-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130274263-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD | 2013-10-17 | — | — | US | disclosed |
| CN-102127056-A | Tubulin inhibitors | CYTOPIA RES PTY LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| EP-1689715-B1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2011-02-09 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| CN-1890218-A | Tubulin inhibitors | CYTOPIA RES PTY LTD (AU) | 2007-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885CDK2 218/4885RET 1618/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | CSF1R 2475/4885CDK2 213/4885RET 1552/4885 |
| US-20130274263-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885CDK2 218/4885RET 1618/4885 |
| US-20140221396-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885CDK2 218/4885RET 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.